Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E3 ubiquitin-protein ligase TRIM56 (TRIM56) is a member of the tripartite motif (TRIM) family and contains a RING domain, B-box domains, a coiled-coil region, and a C-terminal segment essential for its function[1][3][4][5]. TRIM56 acts primarily as an E3 ubiquitin ligase, facilitating the transfer of ubiquitin from E2 enzymes to substrate proteins, thereby regulating their stability, signaling, or localization—a process important for innate immunity, antiviral defense, and cellular homeostasis[1][3][4]. It mediates the K63-linked ubiquitination of STING and monoubiquitinates cGAS, amplifying production of type I interferons and antiviral cytokines in response to dsDNA viruses[1][4]. TRIM56 restricts replication of bovine viral diarrhea virus, dengue virus, yellow fever virus, and porcine epidemic diarrhea virus in an E3 ligase-dependent manner[1][2][5]. In cancer, TRIM56 has dual roles, suppressing ovarian cancer by promoting vimentin degradation, but supporting breast cancer cell proliferation by stabilizing estrogen receptor α[1]. Its gene is inducible by interferon and virus, and its protein expression is regulated by both transcriptional and post-translational events[2][4][5]. Structural studies indicate that TRIM56 assembles into an antiparallel tetramer via its coiled-coil domain, creating a scaffold that facilitates substrate recruitment and ubiquitin transfer activity[1][3].
Not applicable due to lack of direct drug interactions; TRIM56 itself mediates ubiquitination of select proteins involved in antiviral and cellular signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E3 ubiquitin-protein ligase TRIM56 (TRIM56).